[{"orgOrder":0,"company":"Topix Skin Health","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"ProteXidine","moa":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Topix Skin Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Topix Skin Health \/ University of Minnesota","highestDevelopmentStatusID":"1","companyTruncated":"Topix Skin Health \/ University of Minnesota"}]

Find Clinical Drug Pipeline Developments & Deals by Topix Skin Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The partnership aims to develop a proprietary molecule ProteXidine, a biomimetic decoy molecule that enhances the skin's innate ability to manage UV induced damage and inhibit the production of ROS.

                          Brand Name : ProteXidine

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          June 05, 2024

                          Lead Product(s) : ProteXidine

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Sponsor : University of Minnesota

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank